December 2025 — Bristol-Myers Squibb and BioNTech have announced progress in their oncology collaboration with the initiation of a new early-stage clinical trial evaluating pumitamig, an investigational therapy for advanced kidney cancer.
The study, known as ROSETTA RCC-208, is a Phase 1/2 clinical trial designed to assess the safety, tolerability, and early signs of effectiveness of pumitamig in patients with advanced renal cell carcinoma. Bristol-Myers Squibb is leading the study, with BioNTech participating as a development partner.
The trial will evaluate pumitamig both as a standalone therapy and in combination with established cancer treatments. These include the immune checkpoint inhibitor ipilimumab and the targeted therapy cabozantinib. Additional study arms will include standard-of-care regimens such as ipilimumab combined with nivolumab, as well as nivolumab alone, allowing for comparative assessment.
ROSETTA RCC-208 is an open-label, randomized study with multiple parallel treatment groups. The primary focus is on evaluating safety and identifying appropriate dosing levels, while also examining early indicators of anti-tumor activity.
The study is currently listed as not yet recruiting, with protocol updates confirmed in mid-December 2025. Site activation and patient enrollment are expected to follow. Initial completion is anticipated once early safety and response data are collected, with longer-term outcomes such as durability of response and survival to be evaluated later.
For Bristol-Myers Squibb, the trial supports efforts to strengthen and extend its kidney cancer portfolio built around nivolumab and ipilimumab. In a competitive renal cell carcinoma landscape, positive early data could reinforce the company’s long-term positioning.
For BioNTech, the study adds depth to its oncology pipeline beyond vaccines and supports its broader strategy to expand in cancer therapeutics. While early-stage trials carry inherent risk, the initiation of ROSETTA RCC-208 signals continued pipeline momentum for both companies.
Industry observers note that results from this study could influence future treatment strategies in kidney cancer, an area where durable responses remain a significant unmet need.
By
